Johns Hopkins Drug Access and Affordability Initiative
The blueprint seeks to increase competition and improve the negotiation of drug prices, reduce consumers' out-of-pocket spending on medicines, and create incentives to lower list prices.
An antitrust lawsuit against Sacramento, Calif.-based Sutter Health over prices could have a national effect, according to a Kaiser Health News report published by the LA Times.
Gerard Anderson, Professor of Health Policy and Management at Johns Hopkins Bloomberg School of Public Health, speaks about prescription drug costs and President Trump's plan to lower them.
The Johns Hopkins Drug Access and Affordability Initiative focuses on developing bipartisan policy recommendations to address the costs of pharmaceuticals in the United States.
Our proposals attempt to balance the need for innovation, the need to improve patients’ access to medications, and the need to reduce overall medical costs to federal and state governments and other payers in our health care system.
The Latest at JHDAAI
Explore the latest Johns Hopkins Drug Access and Affordability Initiative (JHDAAI) research on Anti Competitive Practices, including on the Orphan Drug Act, Pharmaceutical Benefit Managers, Single Source Generic Drugs, and more.
ACCESS TO MEDICINE: POLICY
Explore the latest JHDAAI research on policy to improve access to medicines, including on Addressing Price Gouging, Hepatitis C in Louisiana, Incorporating Drugs into Bundled Payments and ACOs, and more.
FEDERAL PHARMACEUTICAL SPENDING
Explore the latest JHDAAI research on Federal Pharmaceutical Spending, including on Part D Catastrophic Coverage, Drug Formulary Differences between Medicare, the DOD and the VA, and Drug Prices Paid by Federal Agencies.
This report from the Johns Hopkins Drug Access and Affordability Initiative provides an introduction to trends and reasons for rising drug prices in the United States.